This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           Dec. 25, 2013

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 
As 2013 comes to a close, we at the Society of Gynecologic Oncology wish our members and colleagues throughout the gynecologic oncology community a safe and happy holiday season. This edition of Women’s Cancer News features the most accessed articles since we launched this email publication in June. Our regular publication will resume Thursday, Jan. 2.


Dose-dense carboplatin/paclitaxel may become new standard for ovarian cancer
Healio
From Sept. 4: A dose-dense carboplatin plus paclitaxel treatment regimen may offer a new standard of care for first-line chemotherapy in patients with advanced epithelial ovarian cancer, according to long-term follow-up data from the JGOG 3016 trial.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Cediranib boosts survival in recurrent ovarian cancer
Medscape (Free login required)
From Oct. 2: The investigational agent cediranib can extend survival in women with recurrent ovarian cancer, according to a new study. When given concurrently with platinum-based chemotherapy, there was an approximate 30 percent improvement in progression-free survival. Cediranib continued as maintenance therapy significantly improved both progression-free and overall survival.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Longer wait for uterine cancer surgery reduces survival
HealthDay News via Oncology Nurse Advisor
From Dec. 4: Women who have longer wait times from diagnosis of uterine cancer to definitive surgery have reduced overall survival, according to research published online in the Journal of Clinical Oncology. Lorraine M. Elit, M.D., of McMaster University in Hamilton, Canada, and colleagues analyzed data for 9,417 women with uterine cancer to assess the effect of wait time (from histologic diagnosis to definitive surgery by hysterectomy) on all-cause survival.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  Work for the best

We are seeking a gyn-oncologist to join our growing health system in Springfield, Mo. Our clinic has on-site lab and radiology services, access to a da Vinci® surgical robot and a strong support staff. For more information about this opportunity at our physician owned and operated clinic, call 1-800-869-4201.
 


Targeted treatment plus chemotherapy could benefit women with ovarian cancer
Medical Xpress
From Oct. 16: Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem with a new type of targeted treatment, a new international study shows. The research, published in the October issue of the journal Clinical Cancer Research, provides important evidence that PARP inhibitor drugs and chemotherapy can both be effective in the same patients, helping women live longer than they would if treated with chemotherapy alone.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Improved overall survival confirmed in long-term follow-up report of Japanese dose-dense paclitaxel trial (JGOG 3016)
The Lancet Oncology
From Aug. 28: Long-term follow-up results are now available for JGOG 3016, a randomized, controlled trial of standard carboplatin with paclitaxel administered on either a weekly or conventional, every-three-week schedule. The study enrolled 631 women with stage II-IV ovarian, fallopian tube or primary peritoneal cancer following maximal-effort primary cytoreductive surgery. The median overall survival for the entire cohort after a median of 77 months was 100.5 vs 62.2 months (HR = 0.79, P = .039) favoring the dose-dense treatment group. Five-year overall survival was 58.7 percent vs 51.1 percent for dose-dense vs. conventional, respectively. This is an important finding and is a potential new standard of care for first-line chemotherapy for patients with advanced epithelial ovarian cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Advertisement
A Medical
‘Must Have’

Morrow’s Gynecologic Cancer Surgery, 2nd Edition is an invaluable comprehensive surgical text book resource containing step-by-step written and illustrated descriptions of all the important operations in the field of gynecologic oncology.
Advertisement
Advertise here!

To find out how to feature your company in the SGO News Brief and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE


Model predicts risk of breast and gynecologic cancers
Cancer Network
From Aug. 7: Using easy-to-obtain risk factors for breast, ovarian, and endometrial cancers, researchers have come up with models that can predict an individual woman's absolute risk for developing each type of cancer. While risk models for breast and ovarian cancers have been previously developed, this is the first risk model for endometrial cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Katie Couric show on HPV vaccine sparks backlash
CBS News
From Dec. 11: Katie Couric's talk show "Katie" has drawn ire from doctors and journalists for a recent segment on the HPV vaccine that presented what it called "both sides" of the "HPV controversy." The segment included personal stories from two moms who claim their daughters suffered serious harm from the vaccine (one of them died). In addition, the show featured two physicians: one who researched the vaccine and thinks its long-term protection benefits are oversold, and one who recommends it to her patients, in line with recommendations from the Centers for Disease Control and Prevention and the American Academy of Pediatrics.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Japan withdraws HPV vaccine recommendation for girls
Medscape (Free login required)
From July 3: The Japanese government withdrew its recommendation to use human papillomavirus vaccines in girls, citing concerns from the public about adverse effects, according to news reports. The announcement is in stark contrast to the pronouncement by health officials in the United States that vaccination rates in teenage girls should be increased after a study concluded that estimated vaccine effectiveness is "high."
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Gynecologists run afoul of ABOG when patient is male
The New York Times
From Nov. 27: About two months ago, Dr. Elizabeth Stier was shocked to learn that she would lose a vital credential, board certification as a gynecologist, unless she gave up an important part of her medical practice and her research: taking care of men at high risk for anal cancer. The disease is rare, but it can be fatal and its incidence is increasing, especially among men and women infected with HIV. Like cervical cancer, anal cancer is usually caused by the human papillomavirus, or HPV, which is sexually transmitted.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Hot cancer cells are easier to kill: New drug delivery system uses nanotechnology heating to kill 95 percent of ovarian cancer cells
Medical Daily
From Oct. 23: Heat may be the next big thing in ovarian cancer treatment. In a new study, researchers at Oregon State University have shown that a combination of heat and cytotoxic drugs delivered with nanotechnology can kill up to 95 percent of ovarian cancer cells. The discovery could inspire more effective treatments and prevention strategies for a disease that currently kills more than 150,000 women each year worldwide.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Caitlin McNeely, Content Editor, 469.420.2692  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Dec. 18, 2013
Dec. 11, 2013
Dec. 4, 2013
Nov. 27, 2013






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063